Antithrombotic therapy in unstable angina/non-ST elevation myocardial infarction: The evolving role of low-molecular-weight heparin

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. E, 2000, Pages

  Antman, Elliott M ^a   Kereiakes, Dean J ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

Acute coronary syndromes; Antithrombotic; Low molecular weight heparin

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ELECTROCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTICOAGULANTS; ELECTROCARDIOGRAPHY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0034571723     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Dalen JE, Hirsh J. Fifth ACCP consensus conference on antithrombotic therapy. Chest 1998;114:5439-5748.
2. Cannon CP. Management of Acute Coronary Syndromes. Humana Press: Totowa, New Jersey, 1999: pp. 3-18.
3. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
4. Antman EM, for the TIMI 9A investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624-1630.
5. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa investigators. A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
6. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALK). Circulation 1994;90:1638-1642.
7. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
8. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction. Results of the Thrombosis in Myocardial Infarction (TIMI) IIB Trial. Circulation 1999;100:1593-1601.
9. Barzu T, Molho P, Tobelem G, et al. Binding and endocytosis of heparin by human endothelial cells in culture. Biochem Biophys Acta 1985;845:196-203.
10. Lovenox package insert. Collegeville, Pennsylvania: Pharmaceuticals, Inc., 1998.
11. Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction (1999 update): A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (Committee on Management of Acute Myocardial Infarction). Available at: http://www.acc.org/clinical/guidelines and http://www.americanheart.org
12. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation 1997;96:61-68.
13. Fragmin during instability in coronary artery disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
14. Gurfinkel EP. Low-molecular-weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;2:313-318.
15. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
16. Organization to Assess Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: A randomized trial. Lancet 1999;353:429-438.
17. Rao AK, Sun L, Chesebro, et al. for the Hirudin in Unstable Angina Trial. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina: A multicenter trial. Circulation 1996;94:2389-2395.